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ABSTRACT
Background. Accurate risk stratification and patient
selection is necessary to identify patients who will benefit
the most from surgery or be better treated with other non-
surgical treatment strategies. We sought to identify which
patients in the preoperative setting would likely derive the
most or least benefit from resection of intrahepatic
cholangiocarcinoma (ICC).
Methods. Patients who underwent curative-intent resec-
tion for ICC between 1990 and 2017 were identified from
an international multi-institutional database. A machine-
based classification and regression tree (CART) was used
to generate homogeneous groups of patients relative to
overall survival (OS) based on preoperative factors.
Results. Among 1146 patients, CART analysis revealed
tumor number and size, albumin-bilirubin (ALBI) grade
and preoperative lymph node (LN) status as the strongest
prognostic factors associated with OS among patients
undergoing resection for ICC. In turn, four groups of
patients with distinct outcomes were generated through
machine learning: Group 1 (n = 228): single ICC, size
B 5 cm, ALBI grade I, negative preoperative LN status;
Group 2 (n = 708): (1) single tumor[ 5 cm, (2) single
tumor B 5 cm, ALBI grade 2/3, and (3) single tumor
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B 5 cm, ALBI grade 1, metastatic/suspicious LNs; Group
3 (n = 150): 2–3 tumors; Group 4 (n = 60): C 4 tumors.
5-year OS among Group 1, 2, 3, and 4 patients was 60.5%,
35.8%, 27.5%, and 3.8%, respectively (p\ 0.001). Simi-
larly, 5-year disease-free survival (DFS) among Group 1, 2,
3, and 4 patients was 47%, 27.2%, 6.8%, and 0%,
respectively (p\ 0.001).
Conclusions. The machine-based CART model identified
distinct prognostic groups of patients with distinct out-
comes based on preoperative factors. Survival decision
trees may be useful as guides in preoperative patient
selection and risk stratification.
While a relatively rare cancer, the incidence of intra-
hepatic cholangiocarcinoma (ICC) has increased
worldwide almost threefold over the past three decades.1,2
Surgery remains the mainstay of treatment and the only
chance for long-term survival among patients diagnosed
with ICC. Despite technologic advances and improvements
in surgical techniques, prognosis of patients with ICC still
remains dismal with 5-year overall survival (OS) ranging
from 20 to 40% after curative-intent resection.3,4 In addi-
tion, only one in four patients achieve an optimal textbook
outcome (i.e., R0 resection, no perioperative transfusion,
no postoperative surgical complications, no prolonged
length of stay, no 30-day readmission, and no 30-day
mortality) following surgery for ICC, as many patients
experience some type of complication related to surgery.5
Furthermore, the majority of patients recur within 2 years
of surgery, thereby compromising any chance of long-term
survival.6 As such, patient selection and risk stratification
to identify patients who may be the optimal candidates for
surgery has particular importance for patients with ICC.
Given the general poor prognosis of patients with ICC,
some clinicians have proposed that patients with ICC
should receive neoadjuvant therapy before surgery or even
be treated with other nonsurgical treatment modalities.7 In
turn, several prognostic tools have been developed to
identify patients at risk for adverse outcomes following
ICC resection to help inform preoperative decisions around
treatment.8–10 The majority of these tools have relied,
however, on pathological data, which prevents applicabil-
ity in the preoperative setting.8–10 To this end, Sasaki
et al.11 proposed a preoperative risk score that consisted of
radiologic tumor size and serum biomarkers, including
cancer antigen (CA)19-9, neutrophil-to-lymphocyte ratio,
and albumin, to predict prognosis following resection of
ICC. In addition, our group recently reported that albumin-
bilirubin (ALBI) grade—a marker of underlying liver
function reserve—also was an important predictor of both
short- and long-term outcomes among patients undergoing
surgery for ICC.12 Nevertheless, models based on standard
statistical techniques have been criticized for the discor-
dance in the predicted versus actual postoperative
outcomes, suggesting that preoperative patient risk strati-
fication based on these models may be problematic and
sometimes misleading.13
Survival tree modelling is a machine-learning statistical
technique that recently has been used in health care
increasingly as a means to aid in treatment decision mak-
ing.14,15 Proponents of machine learning include an
unsupervised approach with minimal human intervention
in the model construction, thereby limiting bias and error.
In particular, machine learning is adept at reviewing large
volumes of data and identifying patterns and trends that
might not be apparent to a human. In addition, machine
learning may identify causal relationships that may not
have been evident with other techniques. Because machine
learning technology typically improves efficiency and
accuracy over time as increasing amounts of data are
processed, models based on this approach typically have
improved predictive accuracy.14,15 As such, the objective
of the current study was to identify preoperative factors
that mattered the most in terms of survival following sur-
gery for ICC. Specifically, we sought to identify groups of
patients with distinct outcomes and characterize patients
who derived the most or least benefit from surgery using a
machine learning approach.
METHODS
Study Population and Inclusion Criteria
Patients who underwent curative-intent liver resection
for ICC between January 1990 and December 2017 were
identified using a multi-institutional database. Patients
underwent surgery in one of the following tertiary institu-
tions that made up the International Intrahepatic
Cholangiocarcinoma Study Group; The Ohio State
University Comprehensive Cancer Center, Columbus, OH;
Johns Hopkins Hospital, Baltimore, MD; Stanford
University, Stanford, CA; University of Virginia, Char-
lottesville, VS; Winship Cancer Institute, Emory
University, Atlanta, GA; Fundeni Clinical Institute,
Bucharest, Romania; Scientific Institute San Raffaele,
Vita-Salute San Raffaele University, Milan, Italy; Univer-
sity of Verona, Verona, Italy; Curry Cabral Hospital,
Lisbon, Portugal; Beaujon Hospital, Clichy, France; Eras-
mus University Medical Centre, Rotterdam, Netherlands;
University of Ottawa, Ontario, Canada; Eastern Hepato-
biliary Surgery Hospital, Shanghai, China; Yokohama City
University School of Medicine, Yokohama, Japan; Royal
Prince Alfred Hospital, University of Sydney, Sydney,
Australia. Patients who did not undergo curative-intent
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resection, had concurrent extrahepatic disease at the time
of hepatectomy or had missing follow-up data were
excluded. The Institutional Review Board of all partici-
pating institutions approved this study.
Variables of Interest and Definitions
Demographic and clinicopathologic data included age,
sex, American Society of Anesthesiologists (ASA) score,
preoperative serum CA19-9, and carcinoembryonic antigen
(CEA) levels, ALBI grade, presence of cirrhosis, type of
resection (i.e., minor or major), tumor location (i.e., uni-
focal or multifocal), preoperative lymph node (LN) status
(i.e., negative, suspicious, or positive LNs) and tumor size,
pathologic T and N stage, margin status (i.e., R0, R1, or R2
resection), morphological type (i.e., MF: mass-forming;
IG: intraductal growth; or PI: periductal infiltrating), tumor
grade, presence of major vascular or micro-vascular inva-
sion, as well as receipt of adjuvant chemotherapy.
Pathologic tumor T- and N-stage were defined according
to the American Joint Committee on Cancer (AJCC) 8th
edition staging manual.16 Major hepatectomy was defined
as the resection of three or more Couinaud segments.17
Major vascular invasion was defined as invasion of the
first- and second-order branches of the portal vein or
hepatic arteries or as invasion of one or more of the three
hepatic veins, whereas microvascular invasion was defined
as intraparenchymal vascular involvement identified on
histological examination.16 Furthermore, the ALBI score
was calculated using the following formula: [log10 bilirubin
(lmol/L) 9 0.66] ? [albumin (g/L) 9 -0.085], and
patients were categorized into three groups as follows:
grade 1 B -2.60, grade 2 C -2.60 and B -1.39, and
grade 3 C -1.39.12,18 Information on whether multiple
tumors represented satellite lesions, intrahepatic metas-
tases, or multiple primary tumors was not available; as
such, location of tumor (i.e., unilobar, bilobar) was used as
a surrogate for the purposes of subgroup analysis.
Statistical Analysis
Continuous and categorical variables were presented as
median [interquartile range (IQR)] and frequency (%),
respectively. Differences in baseline characteristics were
assessed using Wilcoxon rank-sum test for continuous and
Chi squared test or Fisher’s exact test for categorical
variables, as appropriate. Overall survival (OS) defined as
the time interval between the date of hepatectomy for ICC
and the date of death or last follow-up was the primary
outcome of the study. Disease-free survival (DFS) was
defined as the time interval between the date of hepatec-
tomy and the date of recurrence or last follow-up.
Differences in survival among groups were assessed by
Kaplan–Meier curves and log-rank test. Statistical signifi-
cance was determined at a = 0.05. Among patients with
multifocal tumors, bivariate, and multivariable cox
regression analyses were performed to assess for factors
associated with survival. Variables significant on bivariate
analysis (p\ 0.05) were entered into the multivariable
model. A nonparametric risk prediction model, known as
Classification and Regression Tree (CART) model, was
used to generate homogeneous groups of patients relative
to OS based on preoperative factors, as previously descri-
bed.14,19 Candidate variables for the survival tree analysis
were limited to those that could be known preoperatively,
including preoperative tumor size and number, as well as
age, gender, ASA class, serum CA 19-9 and CEA levels,
ALBI grade, and preoperative LN status. Missing data were
handled with the use of surrogate splits, which is the
standard way to handle missing data with partykit pack-
age.20,21 In order to reduce overfitting while building the
survival tree, pruning in the training data was performed
using minimum Cook’s D parameter. To assess the possi-
bility of overfitting, ten-fold cross validation was used. To
assess the predictive performance of the final model, the
c-index for time-to-event data was calculated with the
bootstrapping resample method (n = 2000) using the R
CRAN package ipred. All statistical analyses were per-
formed with the SPSS, version 25 statistical package (IBM
Corp. Armonk, NY) and R CRAN software for statistical
computing v. 3.6.0 with the additional packages: survival,
partykit, rpart, Hmisc, caret, ipred, and ROCR.
RESULTS
Demographics of the Analytic Cohort
A total of 1146 patients underwent curative-intent
resection for ICC and were included in the final analytic
cohort (Table 1). Median patient age was 60.4 years (in-
terquartile range [IQR]: 51.7–69.1) and more than half of
patients (n = 638, 55.6%) were male. Median preoperative
CA19-9 and CEA levels were 49.3 UI/mL (IQR:
16.9–211.5) and 2.4 ng/L (IQR: 1.4–4.3), respectively.
Overall, 487 (64.1%) patients had ALBI grade 1, whereas
273 (35.9%) had ALBI grade 2 or 3. The majority of
patients had unifocal disease (n = 844, 81.6%) and
underwent a major liver resection (n = 626, 60.9%).
Median tumor size was 6.0 cm (IQR: 4.0–8.4). On
pathology, 45.8% (n = 521) of patients had T1a/T1b dis-
ease, whereas 27.2% (n = 284) and 17.0% (n = 177) had
N0 and N1 disease, respectively. Most patients had an R0
resection (n = 974, 86.2%) and MF or IG ICC type
(n = 935, 86.9%), whereas only a small subset of individ-
uals had major vascular invasion (n = 157, 13.9%).
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Roughly one-third of patients received adjuvant
chemotherapy (n = 342, 31.3%), whereas only 7.4%
(n = 85) received neoadjuvant chemotherapy (Table 1).
Preoperative CART: Identification of Patients Who will
Benefit the Most from SURGERY
Among preoperative factors, CART analysis revealed
that tumor number and size, ALBI grade and preoperative
LN status were the strongest prognostic factors associated
with OS among patients undergoing resection for ICC
(Fig. 1). Of note, 5-year OS among patients with 1, 2–3,
and[ 3 tumors undergoing resection was 42.1%, 27.5%
and 3.8%, respectively (Supplemental Figure 1a;
p\ 0.001). Among patients with a single tumor, CART
selected tumor size, ALBI grade and preoperative LN
status as the first, second, and third most important pre-
operative factors relative to OS. Of note, patients with an
ICC B 5 cm had a 5-year OS of 52.1%, whereas patients
with larger tumors ([ 5 cm) had a 5-year OS of only
34.4% (Supplemental Figure 1b; p\ 0.001). Among
patients with small (B 5 cm) ICC, patients with ALBI
grade 1 had better OS versus patients with ALBI grade 2/3
(57.9% vs. 41%, p = 0.008). Patients with all four favor-
able characteristics (i.e., single ICC, size B 5 cm, ALBI
grade 1 and negative preoperative LN status) had a 5-year
OS of 60.5%. In contrast, 5-year OS decreased to 36.6%
among patients who had 3 of 4 characteristics (i.e., single
ICC, size B 5 cm, ALBI grade 1) and who had suspicious
LNs based on preoperative assessment (Fig. 1). The model
performed well in both the training (c-index: 0.74) and the
validation dataset with bootstrapping resamples (c-index:
0.67).
Determination of Preoperative Groups: Baseline
Characteristics and Outcomes
The preoperative CART model generated 4 groups of
patients with distinct outcomes: Group 1 (n = 228): single
ICC, size B 5 cm, ALBI grade I, no preoperative LN
metastasis; Group 3 (n = 150): 2–3 tumors; and Group 4
TABLE 1 Clinicopathologic features of patients (N = 1146)
Variable Total, N (%)
Age, median (IQR) 60.4 (51.7, 69.1)
Male 638 (55.6)
ASA
B 2 632 (66.9)
[ 2 312 (33.1)
CA19-9, UI/mL, median (IQR) 49.3 (16.9, 211.5)






Minor resection 402 (39.1)








Tumor size (cm), median (IQR) 6.0 (4.0, 8.4)
AJCC 8th edition T stage
T1a/T1b 521 (45.8)
T2/T3/T4 617 (54.2)









MF, IG 935 (86.9)
PI, MF ? PI 141 (13.1)
Grade
Well to moderate 878 (82.4)















IQR interquartile range, ASA American Society of Anesthesiologist,
CA carbohydrate antigen, CEA carcinoembryonic antigen, MF mass-
forming, IG intraductal growth, PI periductal infiltrating, ALBI
albumin-bilirubin, AJCC American Joint Committee on Cancer
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(n = 60): C 4 tumors. Of note, patients with either a single
tumor[ 5 cm or a single tumor B 5 cm, ALBI grade 2/3
or a single tumor B 5 cm, ALBI grade 1, metastatic/sus-
picious LNs all had a comparable long-term prognosis; in
turn, these patients were categorized in a single cohort as
Group 2 (n = 708; Fig. 1).
Differences in baseline characteristics among the four
groups are summarized in Table 2. Of note, Group 1
patients had lower CA19-9 levels [Group 1: 26.9 UI/mL
(IQR: 13–89.5), Group 2: 55.7 UI/mL (IQR: 19.2–236.7),
Group 3: 76 UI/mL (IQR: 15.4–188.2), Group 4: 204 UI/
mL (IQR: 48–790), p\ 0.001)] and lower CEA levels
[Group 1: 2.2 ng/L (IQR: 1.4–3.3), Group 2: 2.5 ng/L
(IQR: 1.5–4.6), Group 3: 2.2 ng/L (IQR: 1.2–4.3), Group 4:
2.9 ng/L (IQR: 1.7–6.5), p = 0.021)] compared with
patients in Groups 2, 3, and 4 (Table 2). In addition, Group
1 patients more frequently had an R0 resection [Group 1:
212 (93.8%), Group 2: 591 (84.2%), Group 3: 129 (86.6%),
Group 4: 42 (79.2%), p = 0.006)], MF or IG ICC type
[Group 1: 210 (94.6%), Group 2: 566 (85.2%), Group 3:
126 (87.5%), Group 4: 33 (71.7%), p\ 0.001)], and no
major vascular [Group 1: 205 (90.3%), Group 2: 596
(85.1%), Group 3: 131 (87.9%), Group 4: 40 (75.5%),
p = 0.025)] or microvascular invasion [Group 1: 172
(76.8%), Group 2: 472 (67.7%), Group 3: 95 (65.1%),
Group 4: 25 (49.0%), p = 0.001)] compared with the other
CART groups (Table 2). Five-year OS among Groups 1, 2,
3, and 4 patients was 60.5%, 35.8%, 27.5%, and 3.8%,
respectively (Fig. 2a; p\ 0.001). Five-year DFS among
Groups 1, 2, 3, and 4 patients was 47%, 27.2%, 6.8%, and
0%, respectively (Fig. 2b; p\ 0.001). The preoperative
CART model discriminated prognosis better than the 8th
edition of the AJCC T category designations (Fig. 2c) and
performed comparably to the overall 8th edition of the
AJCC staging system (Fig. 2d).
Among patients with multiple tumors (i.e., Groups 3 and
4 patients), patients with unilobar disease had a median and
5-year OS of 20.9 months (95% confidence interval [CI]
17.5–24.2) and 21.5%, respectively, compared with
14.6 months (95% CI 11.3–17.9) and 19.1% among
patients with bilobar disease (p = 0.072). On multivariable
analysis, CA19-9[ 200 UI/mL (hazard ratio [HR] = 2.41,
95% CI 1.59–3.65, p\ 0.001), N1 status (HR = 1.66, 95%
CI 1.09–2.53, p = 0.024), PI/MF ? PI ICC type (HR =
2.32, 95% CI 1.45–3.69, p\ 0.001), as well as poor/un-
differentiated tumor status (HR = 1.57, 95% CI 1.08–2.28,
p = 0.017) were associated with worse survival among
patients with multiple tumors (Table 3).
DISCUSSION
ICC is a rare cancer generally with an aggressive bio-
logic behavior.1,4 Despite curative-intent resection, the
prognosis of patients with ICC still remains dismal with
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FIG. 1 Classification and Regression Tree (CART) model depicting the hierarchical association of preoperative factors relative to 5-year OS
among patients who underwent surgery for ICC
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many patients experiencing a recurrence within 2 years and
less than 40% of patients being alive at 5-years.3,4,6 In turn,
accurate prediction of outcomes and identification of
patients who will derive the most benefit from surgery has
particular importance among patients with ICC. The cur-
rent study was important, because we used a machine-
based approach to identify subsets of patients with distinct
prognosis using preoperative data derived from a CART
model. The CART model facilitated a hierarchical
weighting of the different prognostic factors to identify
which preoperative factors held the most prognostic
impact. Specifically, the CART model identified tumor
number and size, ALBI grade and preoperative LN status
as the most important factors to consider in the preopera-
tive setting. The model identified six nodal points that
translated into four distinct prognostic groups (some nodes
TABLE 2 Differences in baseline characteristics between preoperative groups
Variable Group 1 Group 2 Group 3 Group 4 p value
Age, median (IQR) 58 (49, 69) 60 (52, 69) 63 (54, 70.8) 60.6 (49.9, 69.3) 0.15
Male 153 (67.1) 376 (53.2) 76 (50.7) 32 (53.3) 0.001
ASA \ 0.001
B 2 158 (80.6) 388 (66.6) 66 (54.1) 20 (46.5)
[ 2 38 (19.4) 195 (33.4) 56 (45.9) 23 (53.5)
CA19-9, UI/mL, median (IQR) 26.9 (13, 89.5) 55.7 (19.2, 236.7) 76 (15.4, 188.2) 204 (48, 790) \ 0.001
CEA, ng/L, median (IQR) 2.2 (1.4, 3.3) 2.5 (1.5, 4.6) 2.2 (1.2, 4.3) 2.9 (1.7, 6.5) 0.021
ALBI grade \ 0.001
1 170 (100) 263 (53.9) 42 (57.5) 12 (41.4)
2/3 – 225 (46.1) 31 (42.5) 17 (58.6)
Cirrhosis 43 (18.9) 61 (8.7) 11 (7.3) 8 (13.8) \ 0.001
Type of resection \ 0.001
Minor resection 129 (61.1) 226 (35.2) 35 (27.1) 12 (26.1)
Major resection 82 (38.9) 416 (64.8) 94 (72.9) 34 (73.9)
Preoperative LN status \ 0.001
Negative 196 (100) 420 (73.0) 79 (71.8) 25 (69.4)
Suspicious – 109 (19.0) 23 (20.9) 5 (13.9)
Positive – 46 (8.0) 8 (7.3) 6 (16.7)
Tumor size (cm), median (IQR) 3.6 (2.5, 4.5) 7 (5.2, 9.0) 7 (5.0, 9.0) 7 (5.0, 10.0) \ 0.001
Margin status 0.006
R0 212 (93.8) 591 (84.2) 129 (86.6) 42 (79.2)
R1/R2 14 (6.2) 111 (15.8) 20 (13.4) 11 (20.8)
Morphologic type \ 0.001
MF, IG 210 (94.6) 566 (85.2) 126 (87.5) 33 (71.7)
PI, MF ? PI 12 (5.4) 98 (14.8) 18 (12.5) 13 (28.3)
Grade \ 0.001
Well to moderate 194 (90.7) 547 (82.6) 103 (73.0) 34 (69.4)
Poor to undifferentiated 20 (9.3) 115 (17.4) 38 (27.0) 15 (30.6)
Major vascular invasion 0.025
No 205 (90.3) 596 (85.1) 131 (87.9) 40 (75.5)
Yes 22 (9.7) 104 (14.9) 18 (12.1) 13 (24.5)
Microvascular invasion 0.001
No 172 (76.8) 472 (67.7) 95 (65.1) 25 (49.0)
Yes 52 (23.2) 225 (32.3) 51 (34.9) 26 (51.0)
Median OS, months (95% CI) 79.2 (NR) 36.2 (31.2, 41.1) 21.2 (15.7, 26.8) 14.6 (10.3, 18.9)
5-year OS (%) 60.5% 35.8% 27.5% 3.8%
IQR interquartile range, ASA American Society of Anesthesiologist, CA carbohydrate antigen, CEA carcinoembryonic antigen, MF mass-
forming, IG intraductal growth, PI periductal infiltrating, ALBI albumin-bilirubin, NR not reached
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were merged due to similar outcomes). Using the CART
model, prognostic cohorts that had incrementally worse
survival were defined. For example, patients in Group 1
(i.e., patients with all 4 favorable characteristics; single
ICC, size B 5 cm, ALBI grade I, negative preoperative LN
status) had a 5-year OS of 60.5%, whereas patients in
Group 4 (i.e., patients with C 4 tumors) had an abysmal
5-year OS of only 3.8%. To the best of our knowledge, this
is the first study to utilize a machine-based method as a
means to preoperatively identify different prognostic
groups among ICC patients. In turn, these data may help to
inform presurgical decisions, such as the preferential rou-
tine use of neoadjuvant therapy for patients in prognostic
Group 4.
Machine learning techniques have recently gained
popularity as a means to analyze large volumes of data to
identify patterns and trends that may not be apparent to a
human or evident with other statistical techniques. In
general, machine learning approaches require minimal
human intervention, thus limiting bias and error.14,15
CART analysis is a machine based technique that can
account for complex relationships compared with tradi-
tional statistical methods.22 In particular, CART models
may be helpful decision-making tools and have demon-
strated promise in the field of surgery.14,15,23 For example,
among patients with aggressive malignancies, such as ICC,
CART models may be particularly useful in the selection of
patients for surgery by identifying those individuals who
might benefit more from going directly to surgery versus
being treated with other options, such as neoadjuvant
chemotherapy or locoregional modalities. In addition,
although nomograms have previously been published to
predict outcomes among patients undergoing partial hepa-
tectomy for ICC, these have largely been based on data
derived from the postoperative period (e.g., vascular
invasion, LN metastasis, pathologic tumor size, number,
etc.) and, thus, cannot be applied to patients in the preop-
erative setting.10 In the current study, the CART model
used purely preoperative factors and identified tumor size
and number as the first and second most important
FIG. 2 Kaplan–Meier curve demonstrating differences in OS (a) and
DFS (b) among patients of different preoperative groups. Although
the CART model identified group of patients with incrementally
worse OS, there was poor separation of survival curves among
patients with different T stage disease (c). In contrast, the CART
model could discriminate prognosis well and similarly to the overall
8th edition of the AJCC staging system (d)
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TABLE 3 Factors associated with
survival among patients with
multifocal tumors (n = 210)
Variable Bivariate Multivariable
HR (95% CI) p value HR (95% CI) p value
Age 0.99 (0.98–1.01) 0.38 – –
Gender
Male Ref
Female 0.83 (0.59–1.16) 0.83 – –
ASA
B 2 Ref
[ 2 1.13 (0.78–1.65) 0.52 – –
CA19-9, UI/mL
B 200 Ref Ref
[ 200 3.08 (2.17–4.37) \ 0.001 2.41 (1.59–3.65) \ 0.001
CEA, ng/L
B 5 Ref Ref
[ 5 2.33 (1.65–3.30) \ 0.001 1.45 (0.96–2.18) 0.075
Cirrhosis
No Ref
Yes 1.41 (0.78–2.54) 0.25 – –
ALBI grade
1 Ref
2/3 1.45 (0.89–2.37) 0.14 – –
Location
Unifocal Ref
Multifocal 1.42 (0.97–2.09) 0.07 – –
Tumor size 1.04 (0.99–1.09) 0.10 – –
Tumor number 1.21 (1.11–1.32) \ 0.001 1.03 (0.95–1.12) 0.39
AJCC 8th edition N stage
N0 Ref Ref
N1 1.97 (1.20–3.25) 0.007 1.66 (1.09–2.53) 0.024
Nx 1.25 (0.80–1.96) 0.33 1.38 (0.86–2.22) 0.18
Margin status
R0 Ref Ref
R1/R2 1.86 (1.13–3.05) 0.014 1.41 (0.83–2.41) 0.20
Morphologic type
MF, IG Ref Ref
PI, MF ? PI 2.98 (1.92–4.64) \ 0.001 2.32 (1.45–3.69) \ 0.001
Grade
Well/moderate Ref Ref
Poor/undifferentiated 1.74 (1.20–2.52) 0.004 1.57 (1.08–2.28) 0.017
Major vascular invasion
No Ref
Yes 1.33 (0.85–2.09) 0.22 – –
Microvascular invasion
No Ref
Yes 1.17 (0.82–1.66) 0.39 – –
Adjuvant chemotherapy
No Ref
Yes 0.88 (0.62–1.25) 0.48 – –
Bold values represent statistical significance
ASA American Society of Anesthesiologist, CA Carbohydrate antigen, CEA carcinoembryonic antigen, MF mass-forming,
IG intraductal growth, PI periductal infiltrating, ALBI albumin-bilirubin, AJCC American Joint Committee on Cancer
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preoperative factors associated with prognosis. Of note,
5-year OS incrementally worsened with increasing number
of tumors reaching a 5-year OS of less than 5% among
patients with[ 3 tumors (1, 2–3, and[ 3 tumors: 5-year
OS: 42.1%, 27.5%, and 3.8%, p\ 0.001; Supplemental
Figure 1a). Addeo et al.24 had similarly reported a very low
5-year OS of 7% among patients with multinodular ICC.
Although the 8th edition AJCC staging manual considers
multinodular ICC as a single category (T2 stage) regardless
of the number of tumors, the current study noted that
prognosis incrementally worsened as the actual number of
lesions increased. In examining patients with multiple
tumors, patients with unilobar disease tended to have a
longer median survival compared with individuals who had
bilobar disease. Of note, high CA19-9 levels was particu-
larly associated with a worse survival among patients with
multiple tumors. As such, the data suggest that patients
with multiple tumors—especially those with bilobar dis-
ease and high CA19-9 levels—identified in the
preoperative setting should be strongly considered for
neoadjuvant systemic or locoregional options before con-
templating resection.24–28
Following tumor number, the next variable identified as
being most important relative to prognosis in the CART
model was tumor size. In fact, among patients with a
solitary tumor, tumor size was able to stratify prognosis of
patients based on an ICC tumor size cutoff of[ 5 cm
(B 5 cm 52.1% vs.[ 5 cm ICC 34.4%, p\ 0.001). These
data were consistent with the latest revision of the 8th
edition of the AJCC staging manual.16 The importance of
tumor size in the prognosis of patients with ICC has been
somewhat controversial as the 7th edition of the AJCC
staging manual did not include tumor size.29,30 Subsequent
data suggested, however, that tumor size was indeed
prognostically important. As such, the 8th edition AJCC
staging manual now has two T stage categories for solitary
ICC based on tumor size (single B 5 cm (T1a) and[ 5 cm
(T1b)) .9,16,29 The CART analysis indeed confirmed the
relative importance of tumor size. However, the effect of
tumor size was somewhat mediated by ALBI grade.
Specifically, among patients with single ICC B 5 cm
(T1a), survival outcomes varied considerably with ALBI
grade, which was the next most important predictor of
outcomes in the CART model. In fact, patients with ICC
B 5 cm and ALBI grade 1 had a better OS versus patients
with ALBI grade 2/3 (57.9% vs. 41%, p = 0.008). While
the reason for this is likely multifactorial, a higher ALBI
grade likely acted as a surrogate for liver function
reserve.12,31 Collectively, these data highlight the impor-
tance of the preoperative assessment of liver parenchymal
quality and underlying liver function even among patients
with small (B 5 cm) solitary tumors prior to surgery for
ICC.32 In addition to assessment of liver function, appraisal
of LN status was also important. To this point, patients
with single ICC, size B 5 cm, ALBI grade 1 with no
malignant LN identified on preoperative imaging had a
5-year OS as high as 60.5%. In contrast, patients with the
same favorable characteristics, but who had suspicious or
metastatic LNs identified preoperatively had roughly one-
half the 5-year OS (Fig. 1). Collectively, the CART model
allowed for the identification of four groups of patients
with distinct outcomes following resection for ICC
(Table 2). The clinician simply can follow the paths of the
tree that best describe the characteristics of the patient
being evaluated and can arrive at the prediction of the
outcome of interest for that particular patient.
The current study had several limitations that should be
considered when interpreting the results. As with all ret-
rospective studies, the current study was subject to
selection bias. In addition, although the analysis of data
from multiple centers was a strength, there might have
been some heterogeneity in patient selection and surgical
techniques among the different participating centers.
Although the large number of ICC patients in the cohort
was a strength, the long study period (i.e., 1990–2017) may
have been a source of bias since techniques and perioper-
ative care for ICC patients have changed over the years.
Patients were, however, relatively equally distributed over
the years of the study period. Furthermore, variations may
also exist in the evaluation of tumor size and number in
different centers depending on the method of assessment
and operator expertise. Previous data would suggest,
however, that these differences were unlikely to be
clinically significant.33
CONCLUSIONS
Surgery was associated with dismal prognosis among
certain patients with ICC. Tumor size and number were the
strongest determinants of outcomes prior to surgery and
should guide patient selection. Assessment of liver function
reserve as well as evaluation of preoperative LN status
should also be considered when examining surgery for ICC
patients. In turn, the CART model was able to stratify
patients in 4 groups with a 5-year OS ranging from 60.5 to
3.8%. Patients with multiple tumors, especially those with
bilobar disease and high CA19-9 levels, identified in the
preoperative setting should be strongly considered for
neoadjuvant systemic or locoregional options before con-
templating resection. The machine-based, CART model
could provide an easy to interpret representation of variable
outcomes relative to preoperative factors and could be used
as a guide for preoperative patient selection and risk
stratification.
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